Published in J Biol Chem on June 11, 2004
IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med (2007) 1.34
Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev (2008) 1.14
Role of stem cell factor and bone marrow-derived fibroblasts in airway remodeling. Am J Pathol (2009) 1.02
Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior. J Neuroinflammation (2011) 1.01
Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS One (2012) 0.92
Genome-wide association analysis reveals loci associated with resistance against Piscirickettsia salmonis in two Atlantic salmon (Salmo salar L.) chromosomes. BMC Genomics (2015) 0.89
IL-31-IL-31R interactions limit the magnitude of Th2 cytokine-dependent immunity and inflammation following intestinal helminth infection. J Immunol (2009) 0.88
Definition and characterization of an inhibitor for interleukin-31. J Biol Chem (2010) 0.88
Dendritic cells activated by IFN-γ/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment. J Immunol (2012) 0.86
Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31. Exp Hematol (2007) 0.84
IL-31 does not induce normal human ciliated epithelial cells to differentiate into a phenotype consistent with the pathophysiology of asthma. Results Immunol (2012) 0.78
EP300 Protects from Light-Induced Retinopathy in Zebrafish. Front Pharmacol (2016) 0.78
Molecular dissection of human interleukin-31-mediated signal transduction through site-directed mutagenesis. J Biol Chem (2009) 0.77
Prerequisites for Functional Interleukin 31 Signaling and Its Feedback Regulation by Suppressor of Cytokine Signaling 3 (SOCS3). J Biol Chem (2015) 0.75
The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms. Clin Transl Allergy (2012) 0.75
The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus. Rheumatol Int (2016) 0.75
Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J (2003) 10.77
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol (2002) 9.30
The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity (2003) 5.11
IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol (2007) 2.93
IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res (2003) 2.08
IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J (2003) 2.00
Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol (2003) 1.92
Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol (2011) 1.71
Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity (2013) 1.67
Intrahepatic synthesis of tumor necrosis factor-alpha related to cardiac surgery is inhibited by interleukin-10 via the Janus kinase (Jak)/signal transducers and activator of transcription (STAT) pathway. Crit Care Med (2003) 1.56
SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem (2002) 1.48
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol (2006) 1.43
IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol (2009) 1.42
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 1.38
Real time analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem (2003) 1.38
Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol (2003) 1.36
Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol (2011) 1.35
Nucleocytoplasmic shuttling of persistently activated STAT3. J Cell Sci (2007) 1.31
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother (2007) 1.30
Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J Immunol (2002) 1.29
Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade. J Immunol (2007) 1.27
Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol (2004) 1.25
Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem (2003) 1.25
Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res (2004) 1.20
Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. J Cell Sci (2010) 1.17
Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells. J Cell Sci (2005) 1.16
Interleukin-6 is a direct mediator of T cell migration. Eur J Immunol (2004) 1.13
Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol (2005) 1.13
A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem (2002) 1.12
Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun (2004) 1.11
The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem (2005) 1.10
Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. J Biol Chem (2003) 1.10
Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes. Hepatology (2009) 1.07
Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism. J Biol Chem (2002) 1.04
Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res (2007) 1.02
Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. J Biol Chem (2002) 1.01
STAT3 is enriched in nuclear bodies. J Cell Sci (2003) 1.00
Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK. J Biol Chem (2004) 1.00
Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration. PLoS One (2011) 0.99
The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem J (2004) 0.98
Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src- and receptor-tyrosine kinases. J Biol Chem (2005) 0.98
Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cell Signal (2005) 0.97
Orientational constraints of the gp130 intracellular juxtamembrane domain for signaling. J Biol Chem (2002) 0.97
Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells. J Biol Chem (2003) 0.96
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int (2010) 0.96
STAT5 contributes to interferon resistance of melanoma cells. Curr Biol (2005) 0.96
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother (2009) 0.96
Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol (2008) 0.95
Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol (2004) 0.95
Are STATS arginine-methylated? J Biol Chem (2005) 0.95
A functional role of the membrane-proximal extracellular domains of the signal transducer gp130 in heterodimerization with the leukemia inhibitory factor receptor. Eur J Biochem (2002) 0.95
Interleukin-6 plays a crucial role in the hepatic expression of SOCS3 during acute inflammatory processes in vivo. J Hepatol (2005) 0.95
Activation of NF-kappaB by IL-1beta blocks IL-6-induced sustained STAT3 activation and STAT3-dependent gene expression of the human gamma-fibrinogen gene. Cell Signal (2007) 0.95
Identification of CLEC12B, an inhibitory receptor on myeloid cells. J Biol Chem (2007) 0.93
Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J Invest Dermatol (2005) 0.93
Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthritis Rheum (2009) 0.93
Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism. J Biol Chem (2006) 0.91
Dual function of interleukin-1beta for the regulation of interleukin-6-induced suppressor of cytokine signaling 3 expression. J Biol Chem (2004) 0.91
Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther (2013) 0.89
Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. Biochem J (2002) 0.89
Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. J Immunol (2008) 0.89
Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation. J Biol Chem (2008) 0.89
Novel inhibitors for murine and human leukemia inhibitory factor based on fused soluble receptors. J Biol Chem (2008) 0.88
Development of an IL-6 inhibitor based on the functional analysis of murine IL-6Ralpha(1). Chem Biol (2009) 0.87
IL-31 receptor alpha expression in epidermal keratinocytes is modulated by cell differentiation and interferon gamma. J Invest Dermatol (2008) 0.87
A fusion protein of the gp130 and interleukin-6Ralpha ligand-binding domains acts as a potent interleukin-6 inhibitor. J Biol Chem (2003) 0.86
Polarity and lipid raft association of the components of the ciliary neurotrophic factor receptor complex in Madin-Darby canine kidney cells. J Cell Sci (2004) 0.86
TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex. J Immunol (2003) 0.86
Binding of dynein intermediate chain 2 to paxillin controls focal adhesion dynamics and migration. J Cell Sci (2012) 0.86
Glycosylation analysis of interleukin-23 receptor: elucidation of glycosylation sites and characterization of attached glycan structures. J Mass Spectrom (2010) 0.85
Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinases. Cell Signal (2005) 0.85
An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. J Immunol (2009) 0.85
The chemoattractants, IL-8 and formyl-methionyl-leucyl-phenylalanine, regulate granulocyte colony-stimulating factor signaling by inducing suppressor of cytokine signaling-1 expression. J Immunol (2004) 0.85
Prostaglandin E1 inhibits IL-6-induced MCP-1 expression by interfering specifically in IL-6-dependent ERK1/2, but not STAT3, activation. Biochem J (2008) 0.85
Caspase-dependent cleavage of the mono-ADP-ribosyltransferase ARTD10 interferes with its pro-apoptotic function. FEBS J (2013) 0.84
Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res (2007) 0.84
Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine-binding proteins. J Biol Chem (2006) 0.84
The emerging role of Interleukin 27 in inflammatory arthritis and bone destruction. Cytokine Growth Factor Rev (2012) 0.83
Signal transducer and activator of transcription STAT3 plays a major role in gp130-mediated acute phase protein gene activation. Acta Biochim Pol (2003) 0.83
Three dileucine-like motifs within the interbox1/2 region of the human oncostatin M receptor prevent efficient surface expression in the absence of an associated Janus kinase. J Biol Chem (2005) 0.82
ME3738 protects from concanavalin A-induced liver failure via an IL-6-dependent mechanism. Eur J Immunol (2003) 0.82